Аннотация
Онкофертильность – дисциплина о возможности сохранения репродуктивной функции у пациенток со злокачественными опухолями. Эта новая медицинская дисциплина базируется на двух основных принципах – безопасность и эффективность. Рак молочной железы занимает первое место в структуре онкологической заболеваемости среди женского населения репродуктивного периода. В статье описаны методы сохранения фертильности при раке молочной железы и их эффективность.
Ключевые слова: онкофертильность, рак молочной железы, криоконсервация, ооциты, эмбрионы, яичниковая ткань.
Ключевые слова: онкофертильность, рак молочной железы, криоконсервация, ооциты, эмбрионы, яичниковая ткань.
Об авторе
М.В. Киселева1, М.С. Денисов1, Е.В. Литвякова1, С.А. Иванов1,3, А.Д. Каприн2-4, М.Н. Лунькова1
1 Медицинский радиологический научный центр им. А.Ф. Цыба – филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава России, Обнинск, Россия;
2 ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава России, Обнинск, Россия;
3ФГАОУ ВО «Российский университет дружбы народов» им. Патриса Лумумбы, Москва, Россия;
4 Московский научно-исследовательский онкологический институт им. П.А. Герцена – филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава России, Москва, Россия
m.evtyukhina2010@yandex.ru
Список литературы
1. Каприн А.Д., Старинский В.В., Шахзадова А.О. Состояние онкологической помощи населению России в 2021 г. М., 2022.
[Kaprin A.D., Starinskii V.V., Shakhzadova A.O. Sostoianie onkologicheskoi pomoshchi naseleniiu Rossii v 2021 g. M., 2022 (in Russian).]
2. The Global Cancer Observatory, March, 2021.
3. Trivers KF, Fink AK, Partridge AH et al. Estimates of young breast cancer survivors at risk for infertility in the U.S. Oncologist 2014; 19: 814–22.
4. РосИнфоСтат. Режим доступа: https://rosinfostat.ru
[RosInfoStat. Available at: https://rosinfostat.ru (in Russian).]
5. Бурдяк А.А. Текущие тенденции в социальном развитии (по результатам регулярного Мониторинга ИНСАП РАНХиГС). Экономическое развитие России. 2017; 24 (4).
[Burdiak A.A. Tekushchie tendentsii v sotsial'nom razvitii (po rezul'tatam reguliarnogo Monitoringa INSAP RANKhiGS). Ekonomicheskoe razvitie Rossii. 2017; 24 (4) (in Russian).]
6. Назаренко Т.А., Ашрафян Л.А., Джанашвили Л.Г., Мартиросян Я.О. Сохранение репродуктивного материала у онкологических больных как медико-социальная и организационная проблема. Онкология. Журнал им. П.А. Герцена. 2020; 9 (1): 60–5.
[Nazarenko T.A., Ashrafian L.A., Dzhanashvili L.G., Martirosian Ia.O. Sokhranenie reproduktivnogo materiala u onkologicheskikh bol'nykh kak mediko-sotsial'naia i organizatsionnaia problema. Onkologiia. Zhurnal im. P.A. Gertsena. 2020; 9 (1): 60–5 (in Russian).]
7. Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. Mature oocyte cryopreservation: A guideline. Fertil Steril 2013; 99: 37–43.
8. Anderson RA, Amant F, Braat D et al. ESHRE guideline: Female fertility preservation. Hum Reprod Open 2020; 2020 (4): hoaa052.
9. Lee JR, Choi YS, Jee BC et al. Cryopreserved blastocyst transfer: Impact of gonadotropin-releasing hormone agonist versus antagonist in the previous oocyte retrieval cycles. Fertil Steril 2007; 88: 1344–9.
10. Eftekhar M, Firouzabadi RD, Karimi H, Rahmani E. Outcome of cryopreserved-thawed embryo transfer in the GnRH agonist versus antagonist protocol. Iran J Reprod Med 2012; 10: 297–302.
11. Checa MA, Brassesco M, Sastre M, et al. Random-start GnRH antagonist for emergency fertility preservation: A self-controlled trial. Int J Womens Health 2015; 7: 219–25.
12. Marklund A, Eloranta S, Wikander I et al. Efficacy and safety of controlled ovarian stimulation using GnRH antagonist protocols for emergency fertility preservation in young women with breast cancer-a prospective nationwide Swedish multicenter study. Hum Reprod 2020.
13. Bonardi B, Massarotti C, Bruzzone M et al. Efficacy and Safety of Controlled Ovarian Stimulation With or Without Letrozole Co-administration for Fertility Preservation: A Systematic Review and Meta-Analysis. Front Oncol 2020; 10: 574669.
14. Blakemore JK, Trawick EC, Grifo JA, Goldman KN. Prognostic role of preimplantation genetic testing for aneuploidy in medically indicated fertility preservation. Fertil Steril 2020; 113: 408–16.
15. Sciorio R, Anderson RA. Fertility preservation and preimplantation genetic assessment for women with breast cancer. Cryobiology 2020; 92: 1–8.
16. Ghunaim S, Ghazeeri G, Khalife D, Azim HAJr. Fertility preservation in patients with BRCA mutation. Ecancermedicalscience 2020; 14: 1033.
17. Maman E, Meirow D, Brengauz M et al. Luteal phase oocyte retrieval and in vitro maturation is an optional procedure for urgent fertility preservation. Fertil Steril 2011; 95: 64–7.
18. Chian RC, Uzelac PS, Nargund G. In vitro maturation of human immature oocytes for fertility preservation. Fertil Steril 2013; 99: 1173–81.
19. Diaz-Garcia C, Domingo J, Garcia-Velasco JA et al. Oocytе vitrification versus ovarian cortex transplantation in fertility preservation for adult women undergoing gonadotoxic treatments: A prospective cohort study. Fertil Steril 2018; 109: 478–485.e472.
20. Cobo A, García-Velasco J, Domingo J et al. Elective and Onco-fertility preservation: Factors related to IVF outcomes. Hum Reprod 2018; 33: 2222–31.
21. Perachino M, Massarotti C, Razeti MG et al. Genderspecific aspects related to type of fertility preservation strategies and access to fertility care. ESMO Open 2020; 5: e000771.
22. Cobo A, García-Velasco JA, Remohí J, Pellicer A. Oocyte vitrification for fertility preservation for both medical and nonmedical reasons. Fertil Steril 2021; 115: 1091–101.
23. Oktay K, Turan V, Bedoschi G et al. Fertility Preservation Success Subsequent to Concurrent Aromatase Inhibitor Treatment and Ovarian Stimulation in Women With Breast Cancer. J Clin Oncol 2015; 33: 2424–9.
24. Herraiz S, Cervelló I. New insights for fertility preservation by ovarian tissue cryopreservation and transplantation in pediatric cancer patients. Fertil Steril 2020; 114: 1191.
25. Corkum KS, Rhee DS, Wafford QE et al. Fertility and hormone preservation and restoration for female children and adolescents receiving gonadotoxic cancer treatments: A systematic review. J Pediatr Surg 2019; 54: 2200–9.
26. Wallace WH, Kelsey TW, Anderson RA. Fertility preservation in pre-pubertal girls with cancer: The role of ovarian tissue cryopreservation. Fertil Steril 2016; 105: 6–12.
27. Donnez J, Dolmans MM, Demylle D et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet 2004; 364: 1405–10.
28. Gellert SE, Pors SE, Kristensen SG et al. Transplantation of frozen-thawed ovarian tissue: An update on worldwide activity published in peer-reviewed papers and on the Danish cohort. J Assist Reprod Genet 2018; 35: 561–70.
29. Donnez J, Dolmans MM, Pellicer A et al. Restoration of ovarian activity and pregnancy after transplantation of cryopreserved ovarian tissue:
A review of 60 cases of reimplantation. Fertil Steril 2013; 99: 1503–13.
30. Donnez J, Dolmans MM, Diaz C, Pellicer A. Ovarian cortex transplantation: Time to move on from experimental studies to open clinical application. Fertil Steril 2015; 104: 1097–8.
31. Poirot C, Brugieres L, Yakouben K, et al. Ovarian tissue cryopreservation for fertility preservation in 418 girls and adolescents up to 15 years of agefacing highly gonadotoxic treatment. Twenty years of experience at a single center. Acta Obstet Gynecol Scand 2019; 98: 630–7.
32. Demeestere I, Simon P, Dedeken L et al. Live birth after autograft of ovarian tissue cryopreserved during childhood. Hum Reprod 2015; 30: 2107–9.
33. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: A committee opinion. Fertil Steril 2019; 112: 1022–33.
34. Martinez F. Update on fertility preservation from the Barcelona International Society for Fertility Preservation-ESHRE-ASRM 2015 expert meeting: Indications, results and future perspectives. Hum Reprod 2017; 32: 1802–11.
35. Sheshpari S, Shahnazi M, Mobarak H et al. Ovarian function and reproductive outcome after ovarian tissue transplantation: A systematic review. J Transl Med 2019; 17: 396.
36. Silber S. Ovarian tissue cryopreservation and transplantation: Scientific implications. J Assist Reprod Genet 2016; 33: 1595–603.
37. Herraiz S, Novella-Maestre E, Rodríguez B et al. Improving ovarian tissue cryopreservation for oncologic patients: Slow freezing versus vitrification, effect of different procedures and devices. Fertil Steril 2014; 101: 775–84.
38. Shi Q, Xie Y, Wang Y, Li S. Vitrification versus slow freezing for human ovarian tissue cryopreservation: A systematic review and meta-anlaysis. Sci Rep 2017; 7: 8538.
39. Lee S, Ryu KJ, Kim B et al. Comparison between Slow Freezing and Vitrification for Human Ovarian Tissue Cryopreservation and Xenotransplantation. Int J Mol Sci 2019; 20: 3346.
40. Fabbri R, Vicenti R, Macciocca M et al. Morphological, ultrastructural and functional imaging of frozen/thawed and vitrified/warmed human ovarian tissue retrieved from oncological patients. Hum Reprod 2016; 31: 1838–49.
41. Wang TR, Yan J, Lu CL et al. Human single follicle growth in vitro from cryopreserved ovarian tissue after slow freezing or vitrification. Hum Reprod 2016; 31: 763–73.
42. Dalman A, Farahani NSDG, Totonchi M et al. Slow freezing versus vitrification technique for human ovarian tissue cryopreservation: an evaluation of histological changes, WNT signaling pathway and apoptotic genes expression. Cryobiology 2017; 79: 29–36.
43. Hourvitz A, Yerushalmi GM, Maman E et al. Combination of ovarian tissue harvesting and immature oocyte collection for fertility preservation increases preservation yield. Reprod Biomed Online 2015; 31: 497–505.
44. Delattre S, Segers I, Van Moer E et al. Combining fertility preservation procedures to spread the eggs across different baskets: A feasibility study. Hum Reprod 2020; 35: 2524–36.
45. Fisch B, Abir R. Female fertility preservation: Past, present and future. Reproduction 2018; 156: F11–F27.
46. Vilela JMV, Dolmans MM, Amorim CA. Ovarian tissue transportation: A systematic review. Reprod Biomed Online 2021; 42: 351–65.
47. Roness H, Meirow D. FERTILITY PRESERVATION: Follicle reserve loss in ovarian tissue transplantation. Reproduction 2019; 158: F35–F44.
48. Gao J, Huang Y, Li M et al. Effect of Local Basic Fibroblast Growth Factor and Vascular Endothelial Growth Factor on Subcutaneously Allotransplanted Ovarian Tissue in Ovariectomized Mice. PLoS ONE 2015; 10: e0134035.
49. Kang BJ, Wang Y, Zhang L et al. bFGF and VEGF improve the quality of vitrified-thawed human ovarian tissues after xenotransplantation to SCID mice. J Assist Reprod Genet 2016; 33: 281–9.
50. Mahmoodi M, Mehranjani MS, Shariatzadeh SM, et al. N-acetylcysteine improves function and follicular survival in mice ovarian grafts through inhibition of oxidative stress. Reprod Biomed Online 2015; 30: 101–10.
51. Manavella DD, Cacciottola L, Pommé S et al. Two-step transplantation with adipose tissue-derived stem cells increases follicle survival by enhancing vascularization in xenografted frozen-thawed human ovarian tissue. Hum Reprod 2018; 33: 1107–16.
52. Таджибов С.Н., Поликарпова С.Б., Кочоян Т.М. и др. Метастазы рака молочной железы в яичники. Опухоли женской репродуктивной системы. 2017.
[Tadzhibov S.N., Polikarpova S.B., Kochoian T.M. i dr. Metastazy raka molochnoi zhelezy v iaichniki. Opukholi zhenskoi reproduktivnoi sistemy. 2017 (in Russian).]
53. Rodríguez-Iglesias B, Novella-Maestre E, Herraiz S et al. New methods to improve the safety assessment of cryopreserved ovarian tissue for fertility preservation in breast cancer patients. Fertil Steril 2015; 104 (6): 1493–502.e1-2.
54. Bockstaele L, Boulenouar S, Van Den Steen G et al. Evaluation of quantitative polymerase chain reaction markers for the detection of breast cancer cells in ovarian tissue stored for fertility preservation. Fertil Steril 2015; 104 (2): 410–7.e4.
55. Peters IT, Hilders CG, Sier CF et al. Identification of cell-surface markers for detecting breast cancer cells in ovarian tissue. Arch Gynecol Obstet 2016; 294 (2): 385–93. DOI: 10.1007/s00404-016-4036-7
56. Turan V, Bedoschi G, Emirdar V et al. Ovarian stimulation in patients with cancer: impact of letrozole and BRCA mutations on fertility preservation cycle outcomes. Reprod Sci 2018; 25 (1): 26–32. DOI: 10.1177/1933719117728800
57. De la Noval BD. Potential implications on female fertility and reproductive lifespan in BRCA germline mutation women. Arch Gynecol Obstet 2016; 294 (5): 1099–103. DOI: 10.1007/s00404-016-4187-6.
58. Lambertini M, Goldrat O, Ferreira AR et al. Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients. Ann Oncol 2018; 29 (1): 237–43.
59. Lin WT, Beattie M, Chen LM et al. Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non-clinic-based sample of women in northern California. Cancer 2013; 119 (9): 1652–9. DOI: 10.1002/cncr.27952
60. Peccatori FA, Mangili G, Bergamini A et al. Fertility preservation in women harboring deleterious BRCA mutations: ready for prime time? Hum Reprod 2018; 33 (2): 181–7. DOI: 10.1093/humrep/dex356
61. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997; 350 (9084): 1047–59.
62. Calderon-Margalit R, Friedlander Y, Yanetz R et al. Cancer risk after exposure to treatments for ovulation induction. Am J Epidemiol 2009; 169 (3): 365–75.
63. Källén B, Finnström O, Lindam A et al. Malignancies among women who gave birth after In vitro fertilization. Hum Reprod 2011; 26 (1): 253–8.
64. Brinton LA, Scoccia B, Moghissi KS et al. Long-term relationship of ovulation-stimulating drugs to breast cancer risk. Cancer Epidemiol Biomark Prev 2014; 23 (4): 584–93.
Для цитирования:Киселева М.В., Денисов М.С., Литвякова Е.В., Иванов С.А., Каприн А.Д., Лунькова М.Н. Сохранение фертильности у больных раком молочной железы. Обзор литературы. Клинический разбор в общей медицине. 2023; 4 (12): 51–57. DOI: 10.47407/kr2023.4.12.00331
Журнал предоставляет свободный доступ с возможностью использовать статьи в некоммерческих целях при условии указания авторства в рамках лицензии CC BY-NC-SA 4.0 (https://creativecommons.org/licenses/by-nc-sa/4.0/deed.ru)